Literature DB >> 11259378

Inverse, protean, and ligand-selective agonism: matters of receptor conformation.

T Kenakin1.   

Abstract

Concepts regarding the mechanisms by which drugs activate receptors to produce physiological response have progressed beyond considering the receptor as a simple on-off switch. Current evidence suggests that the idea that agonists produce only varying degrees of receptor activation is obsolete and must be reconciled with data to show that agonist efficacy has texture as well as magnitude. Thus, agonists can block system constitutive response (inverse agonists), behave as positive and inverse agonists on the same receptor (protean agonists), and differ in the stimulus pattern they produce in physiological systems (ligand-selective agonists). The molecular mechanism for this seemingly diverse array of activities is the same, namely, the selective microaffinity of ligands for different conformational states of the receptor. This paper reviews evidence for the existence of the various types of agonism and the potential therapeutic utility of different agonist types.-Kenakin, T. Inverse, protean, and ligand-selective agonism: matters of receptor conformation.

Mesh:

Substances:

Year:  2001        PMID: 11259378     DOI: 10.1096/fj.00-0438rev

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  96 in total

1.  The human 5-HT7 serotonin receptor splice variants: constitutive activity and inverse agonist effects.

Authors:  Kurt A Krobert; Finn Olav Levy
Journal:  Br J Pharmacol       Date:  2002-03       Impact factor: 8.739

2.  V2 vasopressin receptor (V2R) mutations in partial nephrogenic diabetes insipidus highlight protean agonism of V2R antagonists.

Authors:  Kazuhiro Takahashi; Noriko Makita; Katsunori Manaka; Masataka Hisano; Yuko Akioka; Kenichiro Miura; Noriyuki Takubo; Atsuko Iida; Norishi Ueda; Makiko Hashimoto; Toshiro Fujita; Takashi Igarashi; Takashi Sekine; Taroh Iiri
Journal:  J Biol Chem       Date:  2011-12-05       Impact factor: 5.157

3.  Protean agonism at histamine H3 receptors in vitro and in vivo.

Authors:  Florence Gbahou; Agnès Rouleau; Séverine Morisset; Régis Parmentier; Sylvain Crochet; Jian-Sheng Lin; Xavier Ligneau; Joël Tardivel-Lacombe; Holger Stark; Walter Schunack; C Robin Ganellin; Jean-Charles Schwartz; Jean-Michel Arrang
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-05       Impact factor: 11.205

Review 4.  The evolving role of lipid rafts and caveolae in G protein-coupled receptor signaling: implications for molecular pharmacology.

Authors:  Rennolds S Ostrom; Paul A Insel
Journal:  Br J Pharmacol       Date:  2004-08-02       Impact factor: 8.739

Review 5.  Recent advances in drug action and therapeutics: relevance of novel concepts in G-protein-coupled receptor and signal transduction pharmacology.

Authors:  C B Brink; B H Harvey; J Bodenstein; D P Venter; D W Oliver
Journal:  Br J Clin Pharmacol       Date:  2004-04       Impact factor: 4.335

Review 6.  Bradykinin specificity and signaling at GPR100 and B2 kinin receptors.

Authors:  L M Fredrik Leeb-Lundberg
Journal:  Br J Pharmacol       Date:  2004-11-15       Impact factor: 8.739

Review 7.  The significance of G protein-coupled receptor crystallography for drug discovery.

Authors:  John A Salon; David T Lodowski; Krzysztof Palczewski
Journal:  Pharmacol Rev       Date:  2011-12       Impact factor: 25.468

Review 8.  Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery.

Authors:  Terry Kenakin; Laurence J Miller
Journal:  Pharmacol Rev       Date:  2010-04-14       Impact factor: 25.468

9.  Pharmacological characterization of a novel cannabinoid ligand, MDA19, for treatment of neuropathic pain.

Authors:  Jijun J Xu; Philippe Diaz; Fanny Astruc-Diaz; Suzanne Craig; Elizandro Munoz; Mohamed Naguib
Journal:  Anesth Analg       Date:  2010-06-03       Impact factor: 5.108

10.  The G-protein-coupled receptor GCR1 regulates DNA synthesis through activation of phosphatidylinositol-specific phospholipase C.

Authors:  Fabio Apone; Nicole Alyeshmerni; Kathryn Wiens; Derek Chalmers; Maarten J Chrispeels; Gabriella Colucci
Journal:  Plant Physiol       Date:  2003-08-21       Impact factor: 8.340

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.